207 related articles for article (PubMed ID: 31043675)
1. Prognostic role of ARID1A negative expression in gastric cancer.
Ashizawa M; Saito M; Min AKT; Ujiie D; Saito K; Sato T; Kikuchi T; Okayama H; Fujita S; Endo H; Sakamoto W; Momma T; Ohki S; Goto A; Kono K
Sci Rep; 2019 May; 9(1):6769. PubMed ID: 31043675
[TBL] [Abstract][Full Text] [Related]
2. Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer.
Wang X; Che K; Shi T; Liu Q; Xu X; Wu H; Yu L; Liu B; Wei J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1583-1595. PubMed ID: 35294647
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
Tober JM; Halske C; Behrens HM; Krüger S; Röcken C
Hum Pathol; 2019 Dec; 94():98-109. PubMed ID: 31704366
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma.
Zhang Z; Li Q; Sun S; Ye J; Li Z; Cui Z; Liu Q; Zhang Y; Xiong S; Zhang S
Cancer Med; 2023 Aug; 12(16):16716-16733. PubMed ID: 37366273
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of ARID1A in gastric cancer cells: a putative protective molecular mechanism against the Harakiri-mediated apoptosis pathway.
Sakuratani T; Takeuchi T; Yasufuku I; Iwata Y; Saigo C; Kito Y; Yoshida K
Virchows Arch; 2021 Mar; 478(3):401-411. PubMed ID: 32789692
[TBL] [Abstract][Full Text] [Related]
6. Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer.
Qadir J; Majid S; Khan MS; Rashid F; Wani MD; Bhat SA
Pathol Oncol Res; 2021; 27():1609826. PubMed ID: 34924820
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.
Wang DD; Chen YB; Pan K; Wang W; Chen SP; Chen JG; Zhao JJ; Lv L; Pan QZ; Li YQ; Wang QJ; Huang LX; Ke ML; He J; Xia JC
PLoS One; 2012; 7(7):e40364. PubMed ID: 22808142
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of EZH2 and ARID1A expression in urothelial carcinoma: an immunohistochemical study.
Sameh R; Mostafa N; Ramadan M; AbdelRaouf S; Abdelwahab K
J Histotechnol; 2022 Mar; 45(1):21-28. PubMed ID: 34493171
[TBL] [Abstract][Full Text] [Related]
9. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of EBV-positive Gastric Cancers: Loss of PTEN Expression is Associated with Poor Prognosis and Nodal Metastasis.
Kang HJ; Lee IS; Park YS; Ho WJ; Sohn D; Ahn JY; Yook JH; Kim BS
Ann Surg Oncol; 2016 Oct; 23(11):3684-3692. PubMed ID: 27221363
[TBL] [Abstract][Full Text] [Related]
11. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
[TBL] [Abstract][Full Text] [Related]
12. miR-7641 depletion suppresses proliferation of gastric cancer cells by targeting ARID1A.
Yang Y; Yin ZX; Wang ZY; Tian SB; Wang HC; Zhang FX; Li LP; Zheng C; Kong S
Anticancer Drugs; 2020 Apr; 31(4):368-376. PubMed ID: 31913196
[TBL] [Abstract][Full Text] [Related]
13. Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.
Yamada L; Saito M; Thar Min AK; Saito K; Ashizawa M; Kase K; Nakajima S; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Kono K
Gastric Cancer; 2021 Jan; 24(1):60-71. PubMed ID: 32506298
[TBL] [Abstract][Full Text] [Related]
14. Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
Kir G; Soylemez T; Olgun ZC; Aydin A; McCluggage WG
Virchows Arch; 2020 Dec; 477(6):845-856. PubMed ID: 32594230
[TBL] [Abstract][Full Text] [Related]
15. Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer.
Zhu YP; Sheng LL; Wu J; Yang M; Cheng XF; Wu NN; Ye XB; Cai J; Wang L; Shen Q; Wu JQ
Hum Pathol; 2018 Aug; 78():28-35. PubMed ID: 29689245
[TBL] [Abstract][Full Text] [Related]
16. Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma.
Yoshino J; Akiyama Y; Shimada S; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
Carcinogenesis; 2020 Jul; 41(6):734-742. PubMed ID: 31665232
[TBL] [Abstract][Full Text] [Related]
17. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
18. Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.
Han N; Kim MA; Lee HS; Kim WH
Appl Immunohistochem Mol Morphol; 2016; 24(5):320-5. PubMed ID: 26067140
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of ARID1A Expression Patterns Varies with Molecular Subtype in Advanced Gastric Cancer.
Kim JY; Park CK; Noh S; Cheong JH; Noh SH; Kim H
Gut Liver; 2023 Sep; 17(5):753-765. PubMed ID: 36789575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
